Cancer

Mouse studies suggest FLT3 inhibitors could help treat chemotherapy-induced myelosuppression in AML and other cancers. In mice, quizartinib (AC220) transiently decreased the proliferation and size of circulating multipotent progenitor (MPP) cells compared with vehicle. In mice receiving 5-fluorouracil (5-FU), pretreatment with the FLT3 inhibitor quizartinib decreased MPP cell and hematopoietic stem cell (HSC) death, decreased weight loss and increased survival compared with vehicle pretreatment. Next steps could include testing quizartinib in models of other chemotherapy-treated cancers.

Daiichi Sankyo Co. Ltd. has quizartinib in Phase III testing for AML...